Oruka Therapeutics (ORKA) awards CCO 100K shares, 20K option

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) reported that Chief Commercial Officer Larry Todd Edwards received equity awards on August 24, 2026. He was granted 100,000 shares of Common Stock and an option to purchase 20,000 shares of Common Stock at an exercise price of $102.42 per share, both held directly.

The 100,000-share stock grant vests as to one-quarter on September 14, 2027, with the remaining three-quarters vesting in 12 equal quarterly installments thereafter. The 20,000-share option vests as to one-quarter of the underlying shares on August 24, 2027 and then 1/48 of the underlying shares monthly thereafter, and expires on August 23, 2036. The filing does not indicate use of a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 100,000 shares

Net Buy 2 txns

Insider Edwards Larry Todd

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy) F2	20,000	$0.00	$0.00
Grant/Award	Common Stock F1	100,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 20,000 shares (Direct); Common Stock — 100,000 shares (Direct)

Footnotes (2)

1. F1. The grant vests as to 1/4 of the shares on September 14, 2027, with the balance vesting in 12 equal quarterly installments thereafter.
2. F2. The option vests as to 1/4 of the underlying shares on August 24, 2027, and vests as to 1/48 of the underlying shares monthly thereafter.

Key Figures

Common Stock grant: 100,000 shares Option grant underlying shares: 20,000 shares Option exercise price: $102.42 per share +5 more

8 metrics

Common Stock grant 100,000 shares Shares of Common Stock granted on August 24, 2026

Option grant underlying shares 20,000 shares Underlying Common Stock for Employee Stock Option granted on August 24, 2026

Option exercise price $102.42 per share Conversion or exercise price for the Employee Stock Option

Stock grant vesting start September 14, 2027 Date when 1/4 of the 100,000-share stock grant vests

Stock grant remaining vesting schedule 12 equal quarterly installments Schedule for remaining 3/4 of 100,000-share grant after initial vesting

Option vesting initial tranche 1/4 of underlying shares on August 24, 2027 Initial vesting for 20,000-share option

Option vesting thereafter 1/48 of underlying shares monthly Ongoing vesting schedule after initial 1/4 vest for the option

Option expiration date August 23, 2036 Expiration of the 20,000-share Employee Stock Option

Key Terms

Employee Stock Option (right to buy), underlying shares, vests

3 terms

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

underlying shares financial

"The option vests as to 1/4 of the underlying shares"

vests financial

"The grant vests as to 1/4 of the shares on September 14, 2027"

FAQ

What equity awards did ORKA grant to Larry Todd Edwards on August 24, 2026?

On August 24, 2026, Oruka Therapeutics granted Larry Todd Edwards 100,000 shares of Common Stock and an Employee Stock Option for 20,000 shares of Common Stock at an exercise price of $102.42 per share, all held directly.

How does the 100,000-share stock grant to ORKA’s CCO vest?

The 100,000-share Common Stock grant to ORKA’s Chief Commercial Officer vests as to 1/4 of the shares on September 14, 2027, with the remaining 3/4 vesting in 12 equal quarterly installments thereafter, subject to the award’s terms.

What are the vesting terms of Larry Todd Edwards’ 20,000-share stock option at ORKA?

The 20,000-share Employee Stock Option vests as to 1/4 of the underlying shares on August 24, 2027, then 1/48 of the underlying shares monthly thereafter. The option has an exercise price of $102.42 per share and expires on August 23, 2036.

Was the ORKA Form 4 for Larry Todd Edwards filed under a Rule 10b5-1 plan?

No. The Form 4 for Oruka Therapeutics’ Chief Commercial Officer indicates the Rule 10b5-1 checkbox is not selected, and the data does not reference any trading or grant made pursuant to a Rule 10b5-1 plan.

How many ORKA shares does Larry Todd Edwards hold after these reported transactions?

After the reported transactions, Larry Todd Edwards holds 100,000 shares of Common Stock directly and an option for 20,000 underlying shares of Common Stock, according to the post-transaction holdings reported for each award.

What is the expiration date of Larry Todd Edwards’ ORKA stock option?

The Employee Stock Option granted to Larry Todd Edwards by Oruka Therapeutics for 20,000 underlying shares of Common Stock has an expiration date of August 23, 2036, as reported in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/25/2026 - 04:25 PM Accepted by SEC EDGAR 08/25/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Edwards Larry Todd

(Last) (First) (Middle)

ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/24/2026		A		100,000(1)	A	$0	100,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$102.42	08/24/2026		A		20,000		(2)	08/23/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. The grant vests as to 1/4 of the shares on September 14, 2027, with the balance vesting in 12 equal quarterly installments thereafter.

2. The option vests as to 1/4 of the underlying shares on August 24, 2027, and vests as to 1/48 of the underlying shares monthly thereafter.

	/s/ Paul Quinlan, as attorney-in-fact for Larry Todd Edwards	08/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)